Datapoint: GSK Expands Jemperli’s Oncology Reach

The FDA last week granted accelerated approval to GlaxoSmithKline’s Jemperli for the treatment of mismatch repair deficient (dMMR) solid tumors that have progressed despite previous treatment. The PD-1 drug was initially approved in April 2021 for previously treated dMMR endometrial cancer. It holds 55% covered or better status under the medical benefit, and 18% covered or better status under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 8/23/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 6

Datapoint: New Mexico Cancels Medicaid RFP

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 2

Datapoint: Blue Shield of California Launches Virtual-First Plan

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 1

Datapoint: FDA Approves Lilly’s Jaypirca in Blood Cancer

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today